AVEO Terminates RCC Program, Cuts Workforce to Conserve Cash
In the wake of the FDA's Oncology Drugs Advisory Committee (ODAC) 13-1 vote against the adequacy of AVEO Pharmaceuticals Inc.'s tivozanib, an inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in renal cell carcinoma (RCC) there were several losers: patients, the company and its staff.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST